FDA Approves First Targeted Therapy for Metastatic Bladder Cancer

ARTICLES

FDA Approves First Targeted Therapy for Metastatic Bladder Cancer

PRACTICE UPDATE

PUBLISHED: 15 APRIL 2019

The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.